InSysBio CEO Oleg Demin gives a talk at the 6th FIP Pharmaceutical Sciences World Congress2017

events
Conference
May 23, 2017

Moscow, Russia - May 23, 2017. InSysBio CEO Oleg Demin gives a talk at the 6th FIP Pharmaceutical Sciences World Congress2017. He will speak about how to use QSP modeling to investigate drug safety at different stages of development.

Oleg will describe two case studies from the InSysBio practice in his report. The first one concerns Familial Mediterranean Fever (FMF) therapy, which is being developed by R-Pharm pharmaceutical company (Russia). A new drug, which is a protein that binds several mediators of the disease, is now undergoing clinical trials. R-Pharm provided data on preclinical studies on monkeys, and the task of the InSysBio team was to predict the minimal effective dose for human trials, which means striking a balance between efficacy and safety. You will learn from Oleg Demin's presentation how the InSysBio team met this challenge with the help of systems pharmacology tools.

The second case shows how QSP modeling helped to explain the mechanisms of eosinophilia in patients receiving a specific anti-asthma therapy.It is known that an increase in the number of blood eosinophils under asthma pathology is a marker of inflammation. Therefore drugs causing a similar effect were considered not to be safe. However, with the help of system pharmacology modeling, the group led by Tatyana Karelina showed that the substance was not only safe but also effective, and eosinophilia in blood was a consequence of a decrease in inflammation in lungs. You can read more about this case here.

At the end of his report Oleg will present the latest InSysBio scientific developments. He will talk about cutting-edge modeling methods for immunological diseases and medications. In this field it is very dangerous to choose the wrong dose or target: several cases of patients’ deaths at the first stages of clinical trials are known. That's why pharmaceutical companies need to get exact predictions for immune drug development. Come and listen to Oleg's speech about methods for cell dynamics modeling in immunology May 24, 2017 on section Systems pharmacology – innovative approaches to drug safety, Stockholm, Sweden.

March 2019
MoTuWeThFrSaSu
    
1
2
3
4
1. 04 Mar 2019 15:40 12th InSysBio Annual Internal Scientific Meeting 20-22 February 2019 InSysBio company held the 12th Annual Internal Scientific Meeting. Results of the last year and plans for the ongoing year were discussed.
5
6
7
8
9
10
11
12
13
1. 13 Mar 2019 15:50 Tatiana Karelina on TV Tatiana Karelina, Head of the Alzheimer’s Disease modeling group at InSysBio participated in the Russian TV show «Us and science. Science and us».
14
15
16
17
18
19
20
21
22
1. 22 Mar 2019 14:58 InSysBio to present at AACR Annual Meeting 2019 InSysBio announces their participation at American Association for Cancer Research Annual Meeting 2019 being held on March 29 – April 3 in Atlanta, GA
23
24
25
26
1. 26 Mar 2019 19:51 InSysBio to present at PEGS Boston InSysBio announces their participation at 15th Essential Protein Engineering Summit being held on April 8-12 in Boston, MA.
27
28
29
30
31
Upcoming Events
Tags
Latest News
29.10
InSysBio to announce its collaboration with BeOne Medicines
16.10
InSysBio to introduce a new data annotation service available in CYTOCON DB and fIVE DB
19.08
InSysBio to publish the new article "Revolutionizing drug discovery: Integrating artificial intelligence with quantitative systems pharmacology"
05.08
InSysBio to launch Immune Response Template Open for QSP modeling
25.06
InSysBio to announce extension of collaboration with discoveric bio alpha